Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Gerresheimer AG
  6. News
  7. Summary
    GXI   DE000A0LD6E6

GERRESHEIMER AG

(GXI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gerresheimer : is building at the Pfreimd location

06/15/2021 | 05:52am EDT
Gerresheimer production location Pfreimd with new connecting building

Expansion of the clean room area for a major project

Pfreimd, June 15, 2021: Gerresheimer is expanding the production area at one of its larger locations. The new building in Pfreimd offers 1,800 square meters of clean room area of ISO class 8. This construction measure will result in a continuous connection of all clean room areas, so that all loading and unloading procedures in Intralogistics are dispensed with. The new building will be used for setting up additional assembly lines, and the building can be used universally thanks to a flexible usage concept.

Following the expansion of small batch production at the Wackersdorf location and the erection of a new production location in Skopje (North Macedonia), the pharma and medical technology specialist Gerresheimer is also expanding the production capacity at the Pfreimd location with a new building. The new area is required for the major order of a leading pharmaceuticals company. Construction already started in October 2020, and the new building should be completed in August of this year. With an additional 1,800 square meters, the entire clean room area is then expanded to around 20,000 square meters. In Pfreimd, Gerresheimer Medical Systems manufactures products like lab disposables, pen systems, infusion sets, lancing devices, pumps, autoinjectors, inhalers, and catheters for worldwide pharmaceuticals, diagnostics, and medical technology companies.

The new building makes it possible for Gerresheimer to already increase the number of assembly lines at the location to 29 this year. The new, fully automatic lines correspond to the most modern standards, are equipped with Industry 4.0 data analysis systems, and will be connected to an automated guided vehicle system (AGVS). The building itself is conceived of on the basis of our sustainability strategy and contributes to saving CO2 through energy efficiency, as well as heat recovery. The new building is also pre-equipped for the erection of a photovoltaic system, the use of which is currently being tested. 'The new connecting building offers our customers clear advantages for the production of sophisticated pharmaceutical and medical technology products,' explains Oliver Burgel, Global Executive Vice President Operations, Procurement, HR & Quality, Member of the Management Board, Gerresheimer Regensburg GmbH). 'With its highly modern technology, the building is at the same time an important building block for assuring the future of our production facility in Pfreimd.' Thanks to the continuing automation, many attractive workplaces for well-trained specialists will be created in areas like mechatronics, electronics, or IT, among others.

About Gerresheimer

Gerresheimer is the global partner for pharmacy, biotechnology, health and cosmetics, with a very broad product spectrum for drug and cosmetic packaging, as well as drug delivery devices. The company is an innovative provider of solutions, extending from the concept to the delivery of the final product. Gerresheimer achieves its ambitious goals through a high degree of innovative strength, industrial competence, as well as concentration on quality and customer focus. Gerresheimer trusts in an extensive international network with many innovation and production centers in Europe, America, and Asia when developing innovative and sustainable solutions. With around 10,000 employees, Gerresheimer produces close to the customer worldwide and generates an annual turnover of more than 1.4 billion Euro. With its products and solutions, Gerresheimer plays a central role for the health and well-being of people.

Disclaimer

Gerresheimer AG published this content on 15 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 June 2021 09:51:09 UTC.


ę Publicnow 2021
All news about GERRESHEIMER AG
07/28GERRESHEIMER AT CPHI NORTH AMERICA : Innovative packaging and easy administratio..
PU
07/22GERRESHEIMER AG : Release according to Article 40, Section 1 of the WpHG [the Ge..
EQ
07/16GERRESHEIMER AG : Gets a Buy rating from DZ Bank
MD
07/15DGAP-PVR : Gerresheimer AG: Release according to -2-
DJ
07/15DGAP-PVR : Gerresheimer AG: Release according to Article 40, Section 1 of the Wp..
DJ
07/15GERRESHEIMER AG : Release according to Article 40, Section 1 of the WpHG [the Ge..
EQ
07/15GERRESHEIMER AG : Berenberg remains its Buy rating
MD
07/14DGAP-DD : Gerresheimer AG english
DJ
07/14GERRESHEIMER AG : Gets a Buy rating from Credit Suisse
MD
07/14GERRESHEIMER AG : JP Morgan reaffirms its Neutral rating
MD
More news
Financials
Sales 2021 1 466 M 1 741 M 1 741 M
Net income 2021 110 M 131 M 131 M
Net Debt 2021 971 M 1 153 M 1 153 M
P/E ratio 2021 25,1x
Yield 2021 1,48%
Capitalization 2 757 M 3 277 M 3 273 M
EV / Sales 2021 2,54x
EV / Sales 2022 2,35x
Nbr of Employees 10 032
Free-Float 100%
Chart GERRESHEIMER AG
Duration : Period :
Gerresheimer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GERRESHEIMER AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 87,80 €
Average target price 101,38 €
Spread / Average Target 15,5%
EPS Revisions
Managers and Directors
Dietmar Siemssen Chief Executive Officer
Bernd Metzner Chief Financial Officer
Axel Herberg Chairman-Supervisory Board
Theodor Stuth Member-Supervisory Board
Udo Johannes Vetter Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
GERRESHEIMER AG0.06%3 277
ABBOTT LABORATORIES10.49%214 960
MEDTRONIC PLC12.10%176 468
BECTON, DICKINSON AND COMPANY2.36%74 377
ALIGN TECHNOLOGY, INC.30.99%55 063
SARTORIUS STEDIM BIOTECH66.38%52 629